Category: Uncategorized

A group of international researchers has published a noteworthy article concluding that the number of U.S. mesothelioma cases significantly increased from 1999 through 2011, then gradually declined through 2020. The scientists noted the higher incidence of the asbestos-related disease among individuals aged 75 years and older, men, and White populations. The group concludes that enhanced

A group of international researchers has published a noteworthy article concluding that the number of U.S. mesothelioma cases significantly increased from 1999 through 2011, then gradually declined through 2020. The scientists noted the higher incidence of the asbestos-related disease among individuals aged 75 years and older, men, and White populations. The group concludes that enhanced

The family of mesothelioma victim Michael P. Dandry Jr. won an early legal round in its attempt to hold turbine manufacturer Paramount Global responsible for their loved one’s death. The company had filed a motion to have the occupational exposure case against it dismissed, but a U.S. District Court Judge ruled that a reasonable jury

Respected mesothelioma researcher Dr. Jacqueline Moline was in court last week, defending herself against claims of trade libel lodged by Johnson & Johnson’s bankrupt talc subsidiary Pecos River Talc LLC. The company’s previous claim against her had been dismissed based on First Amendment protections, but its attorneys asserted they’d found new information and refiled its

Researchers in China are creating miniaturized versions of mesothelioma tumors to create personalized treatment models for this rare and aggressive cancer. Using malignant ascites, pleural effusions, fine-needle biopsies, and surgical tissues to create patient-derived organoids (PDOs), they hope to improve the poor outcomes and therapy resistance typical of the disease.

According to a report presented at the 2025 ESMO Congress, mesothelioma patients treated with first-line Imfinzi (durvalumab) plus chemotherapy achieved a median overall survival of 21 months compared to 18 months with chemotherapy alone in the phase 3 DREAM3R study. However, slow patient enrollment and shifting standards of treatment complicated the study’s protocol, leading to

Groundbreaking research published in the journal Nature has given rise to hope that mesothelioma patients could experience improved responses to immunotherapy treatment when combined with COVID-19 mRNA vaccines. A collaborative group of scientists from some of the world’s best cancer centers has found that SARS-CoV-2 vaccines sensitize immunologically “cold” tumors to immunotherapy and trigger powerful

Researchers from Cyncado Therapeutics say that TT-4 monotherapy outperforms anti-PD-1 checkpoint inhibitors in treating mesothelioma, and that combining the two improves anti-tumor activity and increased T-cell infiltration even more. The group will be presenting details of its research at the upcoming AACR-NCI-EORTC International Conference to be held in Boston, Massachusetts, this coming weekend.

A Connecticut judge has ordered consumer giant Johnson & Johnson to pay mesothelioma victim Evan Plotkin an additional $10 million in punitive damages. The ruling follows a jury awarding the real estate professional $15 million last October, bringing the total compensation to $25 million. Mr. Plotkin’s lawsuit claimed that decades of personal use of the

According to a report issued by the Australian Institute of Health and Welfare (AIHW), the rate of mesothelioma diagnoses in the country is holding steady, while physicians have made slow improvements in extending lives.